ADRENALIGNE
ActiveSummary
The annual accounts of ADRENALIGNE for financial year 2025 show a net loss of 648% of total assets and of 93% of the equity at the start of that year. The 2025 annual accounts show equity of €278,374 and a net result of -€3.8m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 52% of 318 sector peers (NACE 58, financial year 2025). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
17-07
Gazette deed
Capital & shares · Amendment of the articles · Legal-form change · Resignations & appointments · RestructuringAppointment: LIMBOSCH Cécile (director) · Accounting effect · Shareholding14 facts ▸
- General meeting, 27-06-2025 (2 times)
- Accounting effect, 01-01-2025
- Shareholding
- Merger, “passage de plein droit sans formalité et sans novation, absorption” (deed in French)
- Power of attorney
- Real estate, “propriétaire ou titulaire de droits immobiliers, droit réel”, (...) (deed in French)
- Dissolution, “article 12:13” (deed in French)
- Share cancellation, “actions émises par la société absorbée détenues par la société absorbante, article 12:57 du Code des sociétés et des associations” (deed in French)
- Other provision, “no new shares, article 12:57 du Code des sociétés et des associations” (deed in French)
- Profit allocation, “report”, 11576.55 (deed in French)
- Director appointment, LIMBOSCH Cécile (director)
- Capital conversion, “disponible pour distribution” (deed in French)
- +2 further facts in this act
Show earlier events
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 5 have not been read yet: what they contain is neither established nor disproved here.